8-K: Bausch Health Launches $4 Billion Secured Notes Offering and New Credit Facilities to Refinance Debt

Bausch Health Companies Inc. announces the launch of a $4.0 billion senior secured notes offering and new senior secured credit facilities to refinance existing debt and for general corporate purposes.

Summary

• Bausch Health Companies Inc. has announced the launch of a $4.0 billion offering of new senior secured notes due 2032.
• The company also launched the syndication of new senior secured credit facilities expected to consist of a $400 million revolving credit facility and a $3.4 billion term loan B facility.
• The proceeds from the notes offering and the new term loan facility will be used to repay existing debt, including senior secured notes due in 2025 and 2027, and for general corporate purposes.
• Bausch Health has delivered a notice of conditional redemption for all of its existing notes, with redemption dates in April 2025, contingent upon the consummation of the notes offering and the funding of the new term loan facility.
• The new senior secured credit facilities will be secured by a first priority lien on substantially all assets of the issuer, including a pledge of its direct equity interest in Bausch + Lomb.
• Bausch Health (excluding Bausch + Lomb) reduced net debt by nearly $1 billion in 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The refinancing is a positive step towards managing debt, but the reliance on new debt and the conditional nature of the redemptions introduce some uncertainty.

Positives

• The refinancing aims to improve Bausch Health's debt maturity profile.
• The company reduced net debt by nearly $1 billion in 2024.
• The new credit facilities will replace the existing revolving facility.
• The company has seven consecutive quarters of topand bottom-line growth.

Negatives

• The redemption of existing notes is conditional upon the consummation of the new notes offering and the funding of the new term loan facility, which may be delayed.
• The notes will not be registered under the Securities Act and may only be offered to qualified institutional buyers and non-U.S. persons.
• The company can offer no assurance that the separation (including a potential sale of Bausch + Lomb) will occur on terms or timelines acceptable to the Company or at all.

Risks

• The offering and entry into the new senior secured credit facilities are subject to market and other conditions.
• There is no assurance that the conditions precedent to the redemption of the existing notes will be satisfied or that the redemption will occur.
• The company's ability to consummate the refinancing transactions is subject to market conditions and other significant conditions.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company aims to improve its debt maturity profile and optimize its capital structure, strategically reducing debt leverage and extending maturities to fortify its financial position for long-term success.

Management Comments

• Bausch Health CEO Thomas J. Appio stated that the transaction is part of a broader initiative aimed at opportunistically accessing capital markets to address nearand mid-term maturities.
• Thomas J. Appio stated that the company has a diverse, substantial portfolio of assets and, with seven consecutive quarters of topand bottom-line growth, strong momentum to build on our success in 2025.

Industry Context

Pharmaceutical companies often refinance debt to take advantage of favorable interest rates or to extend maturity dates. This move by Bausch Health is consistent with industry trends of managing debt and optimizing capital structures.

Comparison to Industry Standards

• Comparable companies like Teva Pharmaceutical Industries and Endo International have also undertaken significant debt refinancing activities in recent years.
• The size of Bausch Health's offering is substantial, reflecting the company's significant debt load.
• The interest rates on the new notes and credit facilities will be a key factor in assessing the success of this refinancing compared to industry benchmarks.

Stakeholder Impact

• Shareholders may benefit from the improved debt maturity profile and reduced financial risk.
• Employees may experience greater job security due to the company's improved financial stability.
• Creditors will be impacted by the refinancing of existing debt with new debt instruments.

Next Steps

• Consummation of the offering of the notes.
• Funding of the new term loan facility.
• Redemption of the existing notes.
• Discharge of the indentures governing the 2025 Notes.

Key Dates

Keywords

Bausch Health, Senior Secured Notes, Credit Facilities, Refinancing, Debt, Redemption, Bausch + Lomb